The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Management and outcomes of elderly patients with LBCL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses how the treatment landscape for elderly patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) has evolved over the past few years with the advent of CAR-T therapy. Dr Sureda explains that elderly patients are now included in more clinical trials and a significant proportion can now be cured with second-line axicabtagene ciloleucel (axi-cel). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Honoraria: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Alexion
Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi
Speaker’s Bureau: Takeda
Research support: Takeda, BMS/Celgene
